期刊
JOURNAL OF LIPID RESEARCH
卷 55, 期 9, 页码 1818-1826出版社
ELSEVIER
DOI: 10.1194/jlr.R046599
关键词
epilepsy; Alzheimer's disease; Parkinson's disease; ketoacidosis; hyperketonemia; mitochondrial dysfunction; histone acetylation; 1,3-butanediol monoester of beta-hydroxybutyrate; glyceryl-tris-3-hydroxybutyrate
Ketone bodies (KBs), acetoacetate and beta-hydroxybutyrate (beta HB), were considered harmful metabolic by-products when discovered in the mid-19th century in the urine of patients with diabetic ketoacidosis. It took physicians many years to realize that KBs are normal metabolites synthesized by the liver and exported into the systemic circulation to serve as an energy source for most extrahepatic tissues. Studies have shown that the brain (which normally uses glucose for energy) can readily utilize KBs as an alternative fuel. Even when there is diminished glucose utilization in cognition-critical brain areas, as may occur early in Alzheimer's disease (AD), there is preliminary evidence that these same areas remain capable of metabolizing KBs. Because the ketogenic diet (KD) is difficult to prepare and follow, and effectiveness of KB treatment in certain patients may be enhanced by raising plasma KB levels to >= 2 mM, KB esters, such as 1,3-butanediol monoester of beta HB and glyceryl-tris-3-hydroxybutyrate, have been devised. jlr When administered orally in controlled dosages, these esters can produce plasma KB levels comparable to those achieved by the most rigorous KD, thus providing a safe, convenient, and versatile new approach to the study and potential treatment of a variety of diseases, including epilepsy, AD, and Parkinson's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据